Talya Kupin, MD
Ophthalmology · Delray Beach, FLNPI 1548332497
Payments from drug & device makers
Across 119 payments — averaging $1480.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ocular Therapeutix, Inc.$173K
- AbbVie$732
- Bausch & Lomb Americas Inc.$522
- Alcon$506
- Kerecis Limited$175
- NEW World Medical,inc.$175
- plus $1K from 18 others
Across 1 payment — averaging $2000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$2K
What the payments were for
- Consulting fees$431%
- Food & beverage$3,27599%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ocular Therapeutix, Inc. | 4 | $172,882 |
| AbbVie(2 entities) | 31 | $732 |
| Bausch & Lomb Americas Inc. | 11 | $522 |
| Alcon | 23 | $506 |
| Kerecis Limited | 1 | $175 |
| NEW World Medical,inc. | 4 | $175 |
| Tarsus Pharmaceuticals, Inc. | 2 | $140 |
| Mallinckrodt Hospital Products Inc. | 6 | $111 |
| Aerie Pharmaceuticals, Inc. | 6 | $105 |
| Sight Sciences, Inc. | 5 | $104 |
| Glaukos Corporation | 5 | $100 |
| Alcon Research LLC | 1 | $98 |
| Harrow Eye, LLC | 3 | $84 |
| Sun Pharmaceutical Industries Inc. | 4 | $74 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $68 |
| Shire North American Group Inc | 1 | $43 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $35 |
| Dompe US, Inc. | 1 | $35 |
| Biotissue Holdings Inc. | 1 | $29 |
| Amgen | 1 | $28 |
| Oyster Point Pharma, Inc. | 1 | $27 |
| Thea Pharma Inc. | 1 | $27 |
| Eyevance Pharmaceuticals LLC | 1 | $26 |
| Novartis | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerecis SurgiClose$700
- MIEBO$238
- DURYSTA$236
- Kerecis GraftGuide$175
- Kahook Dual Blade$133
- Clearpath$133
- Ahmed Glaucoma Valve$133
- Streamline$133
- Via360$133
- VYZULTA$124
- XDEMVY$114
- XIIDRA$113
How this compares
$176,144 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 333 | $179,584 |
| RestasisCyclosporine | 113 | $119,085 |
| RhopressaNetarsudil Mesylate | 156 | $86,302 |
| RocklatanNetarsudil Mesylat/Latanoprost | 144 | $83,456 |
| Alphagan PBrimonidine Tartrate | 122 | $67,220 |
| CombiganBrimonidine Tartrate/Timolol | 118 | $54,078 |
| VyzultaLatanoprostene Bunod | 48 | $24,838 |
| Cyclosporine | 29 | $24,790 |
| XiidraLifitegrast | 24 | $21,836 |
| Brinzolamide | 55 | $16,091 |
| Travoprost | 67 | $14,365 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 81 | $13,311 |
| AzoptBrinzolamide | 16 | $11,047 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 43 | $9,252 |
| Latanoprost | 611 | $7,947 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P, Combigan | $732 | $419,967686 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $105 | $169,758300 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $522 | $46,67472 claims |
| AlconAzopt, Simbrinza | $506 | $17,64240 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate, Lotemax Sm | $68 | $13,57445 claims |
| NovartisIlevro | $19 | $4,70912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Delray Beach
- Robert RadenDelray Beach$7.8M
- Bruce SegalDelray Beach$4.7M
- David EichenbaumSt Petersburg$34.4M
- Carl DanzigPompano Beach$5.3M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Matthew CunninghamOrlando$2.9M
- Benjamin ThomasJacksonville$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.